Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel

Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and DocetaxelPosted By Tony Vieira
June 4, 2006

Comments (0)

Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel

Sunday June 4, 8:00 am ET
Alimta Also Shows Tolerability as Triplet Combination Treatment in First-Line Lung Cancer

ATLANTA, Data presented today at the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Ga., affirms that ALIMTA